12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OrBec beclomethasone dipropionate: Phase II started

Soligenix began a double-blind, placebo-controlled Phase II trial to evaluate oral orBec for up to 16 weeks in about 40 patients who have received an allogeneic hematopoietic cell transplantation (HCT) >=100 days earlier, have documented chronic GvHD in >=1 organ outside the GI tract and have a mucosal biopsy consistent with GI GvHD. The trial is partially funded by a 2-year,...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >